Connected Drug Delivery Devices Market Size, Share & Trends Analysis Report By Product, By Route Of Administration (Parenteral, Inhalational), By Application (Asthma, COPD, Diabetes Management, Others), By Region,- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global connected drug delivery devices market size was exhibited at USD 4.88 billion in 2023 and is projected to hit around USD 41.27 billion by 2033, growing at a CAGR of 23.8% during the forecast period 2024 to 2033.

Key Takeaways:

• North America led the global market in 2023 and accounted for a revenue share of over 35% in the year 2023. 
• The standalone components and software segment dominated the market in 2023. 
• The Parenteral devices segment held the highest share of the market in 2023,
• On the basis of application, Diabetes Management dominated the market with a share of over 35% in 2023.

Connected Drug Delivery Devices Market Report Scope

The market is driven by factors such as the need to boost patient medication adherence, R&D activities, and the acceleration of remote digital monitoring conducted by COVID-19. Ypsomed partnered with CamDiab and Abbott to develop and commercialize a new automated insulin delivery system. This initiative aims at integrating Ypsomed’s YpsoPump, with CamDiab’s CamAPS FX App, and Abbott’s FreeStyle Libre sensor. The company intends to complete development by end of 2023.

The COVID-19 pandemic had an overall positive impact on the market with increased awareness of connected devices, adoption by providers & patients, and the importance of remote monitoring for medication adherence. For instance, in 2021 Adherium Limited- a key respiratory eHealth company, reported COVID-driven acceleration in remote patient monitoring across the globe.  The company, however, also faced challenges due to the pandemic in progressing with planned pilot evaluations with partners in the U.S. During 2023, the company expects a strong series of positive commercial and R&D activities owing to the easing of movement restrictions and improved hospital access.

The increasing R&D activities are a key driver for the market. It also contributes to an exponential growth rate owing to the robust product pipeline of several key players anticipated to be launched commercially over the forecast period. In May 2021, Eli Lilly and Company, for example, collaborated with 4 companies - Glooko Inc., DexCom, Inc., Roche, and myDiabby Healthcare- to advance connected solutions for diabetics in markets outside of the U.S. The diabetes management platforms being offered by the companies are expected to be compatible with Lilly's Tempo Pen (available in various markets across the globe) and Tempo Smart Button (in late-stage development) to support diabetes patients, thus propelling the market growth.

The growing need to boost patient medication adherence is another key factor driving the business scope. As more and more patients adopt connected drug delivery devices this would support self-management of their treatment more efficiently, thus helping to reduce the number of visits to clinics and hospitals. Connected devices help with correct dosage and administration and support a successful treatment without the need for costly secondary interventions. These systems also offer reminders and adherence trackers that reduce the patient’s effort to comply with the prescribed medication regime. This can also help reduce the wastage of costly medications such as injectable biologics.

Segments Insights:

Product Insights

The standalone components and software segment dominated the market in 2023. This is due to the increasing demand for connected sensors to transform traditional drug delivery devices into connected drug delivery devices without interfering with their core functionality. The sensors can also be reused even if the device is disposable. Furthermore, the market has witnessed tremendous growth as a result of technological innovation and the increasing connectivity of devices. In February 2023, HeroTracker Sense- a metered-dose inhaler (MDI) add-on was launched by Aptar Pharma- that transforms a standard inhaler into a smart connected drug delivery device.

Integrated devices, on the other hand, are anticipated to grow the fastest at a rate of over 24% during the forecast period. The integrated devices can be employed for injection and Inhalational delivery systems, allowing patients to control their medication therapy even in remote places. The growing availability of integrated connected drug delivery devices is estimated to fuel segment growth. For instance, Elcam's FlexiQ eMU-P connected autoinjector is a self-administration tool for home usage suitable for injection of high-viscosity drugs. It wirelessly transmits injection data to remote storage and also provides calendar settings and injection reminder alerts.

Route Of Administration Insights

The Parenteral devices segment held the highest share of the market in 2023, owing to the numerous advantages offered by smart & connected parenteral devices over conventional ones. The increasing prevalence of chronic diseases such as neurological diseases, diabetes, cancer, and others is also anticipated to drive segment growth during the forecast period. In November 2020, Biocorp launched Mallya- a smart cap for pen injectors that automatically captures data (such as the injection dose, date, and time) and transmits it in real-time via Bluetooth to companion software.

Inhalational devices are projected to grow the fastest at a rate of over 20% during the forecast period. This growth is attributed due to the rising prevalence of respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disorders (COPD), and other respiratory diseases. For instance, according to the Centers for Disease Control and Prevention (CDC), asthma prevalence was estimated at about 25 million across the U.S. in 2020. R&D initiatives and product launches by key companies are also expected to contribute to segment growth in the coming years.

Application Insights

On the basis of application, Diabetes Management dominated the market with a share of over 35% in 2023. This is owing to factors such as the rising prevalence of diabetes, technological advancements, and R&D in insulin delivery devices. For instance, the International Diabetes Federation estimated that about 537 million adults were living with diabetes in 2021. This number is projected to reach 643 million by 2033. The market is anticipated to experience a broad range of developments as connected drug delivery devices are constantly improving, which has the potential to transform the way diabetes is managed.

The other Applications segment is anticipated to grow the fastest at a rate of more than 24% in the next few years. It comprises autoimmune diseases such as multiple sclerosis, migraine, and osteoporosis. In December 2019, the YpsoMate prefilled autoinjector by Ypsomed was selected by Terumo Corporation to assemble its PLAJEX syringe with the osteoporosis drug- Teribone (developed by Asahi Kasei Pharma). The final product was launched in Japan. Similar partnerships and collaborations are expected to propel the segment's growth. 

Regional Insights

North America led the global market in 2023 and accounted for a revenue share of over 35% in the year 2023. This is due to the region’s high per capita healthcare spending, rapid adoption of technology presence of key players, and growing adoption of remote monitoring for medication adherence. Cognita Labs, LLC for instance, is headquartered in the U.S. and has developed CapMedic (a Class II device) that works as an inhaler attachment for MDI. It measures the correctness of inhaler use, frequency, and time of its use and provides audio-visual interactive guidance in real-time on correct usage.

Due to the rising prevalence of chronic diseases and the availability of a huge patient population base, the Asia Pacific region is anticipated to have the fastest growth at a rate of over 24% over the forecast period. The growing number of companies and initiatives deployed by them is also expected to fuel regional growth. Adherium for instance, is a New Zealand-based public company focused on developing solutions for remote monitoring, patient adherence, and data management in the respiratory area. 

Some of the prominent players in the Connected drug delivery devices market include:

• Teva Respiratory, LLC
• Novo Nordisk A/S
• Phillips-Medisize, LLC
• Medtronic
• Adherium Limited
• Tandem Diabetes Care, Inc.
• Biocorp
• Propeller health
• Ypsomed AG
• Aptar Pharma

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global connected drug delivery devices market.

Product Type

• Standalone Components & Software
• Integrated Devices

Route of Administration

• Parenteral
• Inhalational

Application

• Asthma
• COPD
• Diabetes Management
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)